Financial Comparison: FibroGen (FGEN) & Cellular Dynamics International (ICEL)
FibroGen (NASDAQ: FGEN) and Cellular Dynamics International (NASDAQ:ICEL) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations.
Valuation and Earnings
This table compares FibroGen and Cellular Dynamics International’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|FibroGen||$117.90 million||34.12||-$110.06 million||($1.92)||-29.43|
|Cellular Dynamics International||N/A||N/A||N/A||N/A||N/A|
Institutional & Insider Ownership
47.5% of FibroGen shares are held by institutional investors. 14.9% of FibroGen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This is a summary of recent recommendations for FibroGen and Cellular Dynamics International, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cellular Dynamics International||0||0||0||0||N/A|
FibroGen presently has a consensus price target of $65.67, indicating a potential upside of 16.22%. Given FibroGen’s higher probable upside, equities research analysts plainly believe FibroGen is more favorable than Cellular Dynamics International.
This table compares FibroGen and Cellular Dynamics International’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cellular Dynamics International||-88.12%||-57.59%||-38.09%|
FibroGen beats Cellular Dynamics International on 7 of the 9 factors compared between the two stocks.
FibroGen Company Profile
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.
Cellular Dynamics International Company Profile
Cellular Dynamics International, Inc. develops and produces functioning human cells in industrial quantities. The Company’s products include true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell products). It markets its products for use in life science in vitro research and development, as well as applied product testing, stem cell banking and in vivo cellular therapeutics. It is also in the process of developing human cells as cellular therapeutics. The market for in vitro drug discovery, toxicity testing and applied testing, including chemical safety, has employed models, such as primary cells, transformed (immortalized) cells and live animals that act as surrogates for functioning human cells. Its iCell and MyCell products consist of iCell Cardiomyocytes, iCell Neurons, iCell DopaNeurons, iCell Endothelial Cells, iCell Hepatocytes, MyCell and Media and reprogramming kit.
Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.